BenchSci, a leading provider of AI software for biopharma research and development, and Mila - Quebec Artificial Intelligence Institute, one of the world's premier AI research centers, today announced ...

ATRN-119 is being evaluated in the open-label Phase 1/2a clinical trial (ABOYA-119) as monotherapy in patients with advanced solid tumors having at least one mutation in a defined panel of DDR-related ...